Cytochrome bc1 Inhibitors: Future Tuberculosis Treatments

Publication date: Oct 23, 2025

Unlike broad-spectrum antibiotics that often affect multiple bacterial pathways and can cause host toxicity, bc1 inhibitors are highly selective for the bacterial enzyme complex. The role of cytochrome bc1 inhibitors in future tuberculosis treatment regimens. Cytochrome bc1 inhibitors serve as proof-of-concept molecules demonstrating how targeting bacterial respiration can be a potent antimicrobial strategy. The detailed knowledge of bacterial bioenergetics and enzyme structure has been pivotal in guiding the synthesis of tailored inhibitors. Traditional TB therapy commonly requires six months or more of drug administration, contributing to compliance issues and the emergence of drug resistance. Incorporating high-throughput screening methods specifically aimed at respiratory enzyme complexes could accelerate the identification of drug candidates. Disrupting this complex cripples the energy production of M. tuberculosis, rendering it incapable of maintaining its metabolic functions and survival.

Semantics

Original Article